GENERIC PEPTIDE • LIRAGLUTIDE Liraglutide Liraglutide Sequence: H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(γ-Glu-palmitoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH Liraglutide Applications: Liraglutide in a once-a-day injectable Glucagon-Like Peptide-1 agonist (GLP-1 agonist) used for the treatment of type 2 diabetes. It is an incretin mimetic stimulating the release and synthesis of insulin into the blood by the intestine in response to food. It is only active in the presence of high circulating glucose levels. It also slows the passage of food through the gut and reduces appetite. Liraglutide Produced in: Torrance, US Documents available: N/A Liraglutide Safety Data Sheet: Liraglutide Safety Data Sheet See all products ASK FOR A QUOTE CONTACT US POLYPEPTIDE GROUP INFO INVESTORS CORPORATE NEWS OUR STORIES ABOUT US MEDIA CONTACT CONTACT US QUOTATION REQUEST CAREERS SOCIALS LINKEDIN FACEBOOK TWITTER YOUTUBE © Confidentiality 2021 PolyPeptide Group • Cookie management • Personal data • Sitemap ACTH (1-39) PorcineAtosibanCalcitoninCarbetocinDeslorelinDesmopressinExenatideFelypressinLeuprolideLiraglutideOctreotidePTH (1-34) TeriparatideSemaglutideSomatostatinTriptorelinVasopressin, 8-L-Arginine By clicking “Accept”, you consent to the use of ALL the cookies on our website . However you may visit Cookie Settings to provide a controlled consent. Cookie settingsACCEPT